Quidel to Present at the 29th Annual Piper Jaffray Healthcare Conference
November 15 2017 - 4:05PM
Business Wire
Quidel Corporation (NASDAQ: QDEL), a provider of rapid
diagnostic testing solutions, cellular-based virology assays and
molecular diagnostic systems, announced today that it will present
at the 29th Annual Piper Jaffray Healthcare Conference, to be held
at the Lotte New York Palace hotel in New York, New York on
Tuesday, November 28, 2017.
Douglas Bryant, president and chief executive officer, and Randy
Steward, chief financial officer, will present that day at 9:00
a.m. Eastern time (6:00 a.m. Pacific time) with a question and
answer session scheduled immediately following the presentation.
During the presentation, the company will discuss business and
financial developments and trends. The company's statements may
contain or constitute material information that has not been
previously disclosed.
A live webcast and audio archive of each presentation will be
available via the Investor Relations section of the company’s Web
site at http://ir.quidel.com or by clicking on the following
link:
https://event.webcasts.com/starthere.jsp?ei=1171839&tp_key=53077f12e7
Participants should allow approximately five to ten minutes
prior to the presentation's start time to visit the site and
download any streaming media software needed to listen to the
Internet webcast. A replay of the webcast will also be available on
the company’s Web site for 14 days.
About Quidel Corporation
Quidel Corporation serves to enhance the health and
well-being of people around the globe through the development of
diagnostic solutions that can lead to improved patient outcomes and
provide economic benefits to the healthcare system. Marketed under
the Sofia®, QuickVue®, D3® Direct Detection, Thyretain®, Triage®
and InflammaDry® leading brand names, as well as under the new
Solana®, AmpliVue® and Lyra® molecular diagnostic brands, Quidel’s
products aid in the detection and diagnosis of many critical
diseases and conditions, including, among others, influenza,
respiratory syncytial virus, Strep A, herpes, pregnancy, thyroid
disease and fecal occult blood. Quidel's recently
acquired Triage® system of tests comprises a comprehensive test
menu that provides rapid, cost-effective treatment decisions at the
point-of-care (POC), offering a diverse immunoassay menu in a
variety of tests to provide you with diagnostic answers for
quantitative BNP, CK-MB, d-dimer, myoglobin, troponin I and
qualitative TOX Drug Screen. Quidel’s research and development
engine is also developing a continuum of diagnostic solutions from
advanced immunoassay to molecular diagnostic tests to further
improve the quality of healthcare in physicians’ offices and
hospital and reference laboratories. For more information about
Quidel’s comprehensive product portfolio,
visit quidel.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171115006324/en/
Quidel Contact:Quidel CorporationRandy StewardChief Financial
Officer(858) 552-7931orMedia and Investors Contact:Quidel
CorporationRuben Argueta(858) 646-8023rargueta@quidel.com
QuidelOrtho (NASDAQ:QDEL)
Historical Stock Chart
From Mar 2024 to Apr 2024
QuidelOrtho (NASDAQ:QDEL)
Historical Stock Chart
From Apr 2023 to Apr 2024